Page last updated: 2024-12-05

3-hydroxybiphenyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-hydroxybiphenyl is a phenolic compound that has been studied for its potential biological activities. It has been shown to exhibit antioxidant and anti-inflammatory properties, and it has been investigated for its potential use in the treatment of various diseases. The synthesis of 3-hydroxybiphenyl typically involves the reaction of 3-bromobiphenyl with potassium hydroxide. 3-hydroxybiphenyl has been found to inhibit the growth of cancer cells in vitro, suggesting its potential as a chemotherapeutic agent. Further research is needed to fully understand the biological effects of 3-hydroxybiphenyl and its potential therapeutic applications.'

3-hydroxybiphenyl: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

biphenyl-3-ol : A member of the class of hydroxybiphenyls that is phenol in which the hydrogen at position 3 has been replaced by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11381
CHEMBL ID122570
CHEBI ID34338
SCHEMBL ID51869
MeSH IDM0166517

Synonyms (48)

Synonym
BIDD:ER0167
nsc 17588
zu11x47h4o ,
unii-zu11x47h4o
(1,1'-biphenyl)-3-ol
CHEBI:34338 ,
m-phenylphenol
580-51-8
m-hydroxydiphenyl
biphenyl-3-ol
3-phenylphenol
[1,1'-biphenyl]-3-ol
3-hydroxybiphenyl
nsc17588
m-hydroxybiphenyl
3-biphenylol
nsc-17588
3-hydroxydiphenyl
3-hydroxy-biphenyl
inchi=1/c12h10o/c13-12-8-4-7-11(9-12)10-5-2-1-3-6-10/h1-9,13
3-phenylphenol, 85%
CHEMBL122570
P0768
AKOS002678496
A831714
FT-0616342
SCHEMBL51869
phenol, m-phenyl-
3-phenyl phenol
3-phenyl-phenol
3-phenyphenol
3-hydroxy biphenyl
dtxcid602462
tox21_303813
NCGC00356994-01
cas-580-51-8
dtxsid2022462 ,
mfcd00002294
3-phenylphenol,90% remainder 4-phenylphenol
DS-5096
Q27115998
BBL019899
STL196681
AMY38615
D70321
SY051510
EN300-122583
CS-W017699
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxybiphenylsAny member of the class of biphenyls that has one or more hydroxy groups attached to the benzenoid ring system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency35.57420.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.56560.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency43.78240.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency9.59030.000221.22318,912.5098AID1259243; AID1259247
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency35.85580.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency39.83230.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency30.63790.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency16.29210.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.58100.001530.607315,848.9004AID1224841; AID1224849; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency48.55770.005428.02631,258.9301AID1346982
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency42.12180.057821.109761.2679AID1159526; AID1159528
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1486519Binding affinity to transthyretin in human blood plasma assessed as plasma binding selectivity by measuring stoichiometry of small molecule bound to TTR incubated for 24 hrs at 37 degC by RP-HPLC2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID479386Displacement of [3H]estradiol from human placental 17beta-HSD2 at 1 uM2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
AID479385Displacement of [3H]estrone from human placental 17beta-HSD1 at 1 uM2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1306172Cytotoxicity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1486518Inhibition of acid-induced wild type transthyretin (unknown origin) aggregation expressed in Escherichia coli pre-incubated for 30 mins before acid addition and further incubated for 72 hrs at 37 degC under dark conditions by UV-Vis spectrophotometry2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID624614Specific activity of expressed human recombinant UGT2A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1306175Therapeutic index, ratio of IC50 for HEK293 cells to IC50 for human MCF7 cells2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1306171Cytotoxicity against HEK293 cells assessed as reduction in cell growth after 3 days by MTT assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1306174Therapeutic index, ratio of IC50 for HEK293 cells to IC50 for human HT-29 cells2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID89369Transthyretin (TTR) amyloidogenesis inhibition activity by employing an acid-mediated (pH 4.4) WTTTR amyloid fibril formation assay, at 7.2 uM conc.2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1306173Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 3 days by MTT assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's2 (22.22)18.2507
2000's2 (22.22)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.18 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]